drugset / Trial / NCT03035734

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

NCT03035734

Phase 1 Withdrawn Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

Open label, randomized, 4-period crossover study with single doses of BMS-986141 given to healthy female subjects of non-childbearing potential and healthy males.

Timeline

Start
2017-01-25
Primary completion
2017-02-07
Completion
2017-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986141 Small molecule Oral

Indications

No indication recorded.